2seventy bio, Inc.
TSVT
$4.98
$0.010.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -72.61% | 12.46% | -75.12% | -70.12% | -80.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -72.61% | 12.46% | -75.12% | -70.12% | -80.98% |
| Cost of Revenue | -67.82% | -74.97% | -69.82% | -33.24% | -15.89% |
| Gross Profit | 66.64% | 98.75% | 63.10% | -16.41% | -416.31% |
| SG&A Expenses | -47.39% | -0.92% | -49.42% | -38.90% | -13.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -63.13% | -61.07% | -65.09% | -34.50% | -15.33% |
| Operating Income | 61.43% | 76.53% | 57.54% | 5.78% | -120.47% |
| Income Before Tax | 65.65% | 86.13% | 159.11% | -12.02% | -145.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.65% | 86.13% | 159.11% | -12.02% | -145.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.65% | 86.13% | 159.11% | -12.02% | -145.53% |
| EBIT | 61.43% | 76.53% | 57.54% | 5.78% | -120.47% |
| EBITDA | 62.29% | 78.38% | 59.12% | 5.75% | -128.91% |
| EPS Basic | 66.27% | 86.42% | 157.73% | 6.48% | -84.84% |
| Normalized Basic EPS | 66.53% | 81.86% | 61.90% | 19.72% | -85.07% |
| EPS Diluted | 66.27% | 86.42% | 154.22% | 6.48% | -84.84% |
| Normalized Diluted EPS | 66.53% | 81.86% | 63.86% | 19.72% | -85.07% |
| Average Basic Shares Outstanding | 1.85% | 2.12% | 2.39% | 19.79% | 32.84% |
| Average Diluted Shares Outstanding | 1.85% | 2.12% | 7.94% | 19.79% | 32.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |